127 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
to fiscal 2022. Non-cash expenses associated with equity remuneration increased by $1.4 million in fiscal year 2023 over 2022. Payroll and benefits … ®, the market opportunity for and market impact of PEDMARK®, its potential impact on patients and anticipated benefits associated with its use
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
Rosty Raykov, Chief Executive Officer of Fennec Pharmaceuticals. “From a deal perspective, the terms provided us many important benefits, including … impact of PEDMARK and PEDMARQSI, its potential impact on patients and anticipated benefits associated with its use, and potential access to further
424B7
FENC
Fennec Pharmaceuticals Inc
15 Mar 24
Prospectus with selling stockholder info
3:53pm
, PEDMARK® (known as PEDMARQSI® in the European Union);
the benefits of the use of PEDMARK®;
our ability to successfully commercialize PEDMARK®;
the rate … and degree of market acceptance of PEDMARK®;
our ability to maintain, or recognize the anticipated benefits of, orphan drug designation for PEDMARK®
8-K/A
EX-99.1
9sbmhqr
6 Mar 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:07pm
8-K
EX-99.1
oiu5p3xd
29 Feb 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:04pm
8-K
EX-4.1
1m7nz4 zqslcu330v40
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
8-K
EX-99.1
wnrfk83zifr 04
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
8-K
EX-99.1
8tjd5
6 Nov 23
Fennec Pharmaceuticals Announces Third Quarter 2023
7:38pm
8-K/A
5rcy2pxu4q
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K/A
EX-10.1
wz9gdl36 d7
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K/A
EX-99.1
dpa5h
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
EX-10.1
csfy fz10
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am
8-K
qlkgk
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am